CervoMed logo

CervoMedNASDAQ: CRVO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 May 2008

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$115.14 M
-43%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-93%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 7 min ago
$13.95+$0.50(+3.72%)

Dividend

No data over the past 3 years
$3.07 M$3.07 M

Analysts recommendations

Institutional Ownership

CRVO Latest News

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
globenewswire.com04 November 2024 Sentiment: -

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
globenewswire.com29 October 2024 Sentiment: POSITIVE

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the eighth International Lewy Body Dementia Conference (ILBDC) taking place on January 29-31, 2025 in Amsterdam, the Netherlands. “As we await topline results from the RewinD-LB Phase 2b trial in DLB, we are extremely encouraged by the scientific community's interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to Lewy Body Dementia,” said John Alam, MD, Chief Executive Officer of CervoMed.

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
zacks.com20 September 2024 Sentiment: POSITIVE

CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
globenewswire.com22 August 2024 Sentiment: POSITIVE

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
globenewswire.com30 July 2024 Sentiment: POSITIVE

BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
Seeking Alpha02 April 2024 Sentiment: POSITIVE

Results from the phase 2b RewinD-LB study, using neflamapimod for the treatment of patients with Dementia With Lewy bodies, are expected in the 2nd half of 2024. The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033. If targeting of p38 alpha protein to inhibit synaptic dysfunction works for DLB, then potential to apply the same mechanism of action towards Alzheimer's Disease, Frontotemporal dementia, and other neurological disorders.

CervoMed to Participate in Upcoming Investor Conferences
GlobeNewsWire28 March 2024 Sentiment: POSITIVE

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in the following three investor conferences during the month of April:

What type of business is CervoMed?

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

What sector is CervoMed in?

CervoMed is in the Healthcare sector

What industry is CervoMed in?

CervoMed is in the Biotechnology industry

What country is CervoMed from?

CervoMed is headquartered in United States

When did CervoMed go public?

CervoMed initial public offering (IPO) was on 23 May 2008

What is CervoMed website?

https://www.cervomed.com

Is CervoMed in the S&P 500?

No, CervoMed is not included in the S&P 500 index

Is CervoMed in the NASDAQ 100?

No, CervoMed is not included in the NASDAQ 100 index

Is CervoMed in the Dow Jones?

No, CervoMed is not included in the Dow Jones index

When was CervoMed the previous earnings report?

No data

When does CervoMed earnings report?

The next expected earnings date for CervoMed is 13 November 2024